NICE rejects infliximab treatment for subacute ulcerative colitis

The National Institute for Health and Clinical Excellence (NICE) has not recommended infliximab for subacute moderately to severely active ulcerative colitis.

NICE's technology appraisal committee found that using infliximab in these circumstances did not offer value for money to the NHS.
 
Professor Peter Littlejohns, NICE clinical and public health director and executive lead for the appraisal, said: 'The committee concluded that the technology could not be considered a cost-effective use of NHS resources and so could not recommend its use.'

Later this year, NICE will publish guidance on the use of infliximab for the treatment of acute manifestations of the condition.

Ulcerative colitis is a disease that causes inflammation of the large intestine or colon and symptoms vary from pain and discomfort, mucus in stools and in severe cases, blood in stools.